First-in-human study plans to enroll healthy volunteers and adults with Type 1 or Type 2 diabetes to evaluate PAL-119’s safety and tolerability and explore its effects on the body’s own insulin production SAN DIEGO, Nov. 2, 2026 /PRNewswire/ — Paulex Bio Inc., a biopharmaceutical company…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
